Trodelvy

October 15, 2020October 15, 2020

Trodelvy Shows Superiority to Chemo for Advanced TNBC in Phase 3 Trial

News

Trodelvy (sacituzumab govitecan), compared with standard chemotherapy, significantly prolonged overall survival and improved the overall response rate of patients with metastatic triple-negative breast cancer (mTNBC) who had at least two prior ... Read more

July 16, 2020July 16, 2020

Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows

News

Immunomedics has announced that its Phase 3 ASCENT trial of Trodelvy (sacituzumab govitecan) met its main goal of demonstrating that the medication is superior to standard chemotherapy at delaying disease ... Read more

April 23, 2020April 23, 2020

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

News

The U.S. Food and Drug Administration (FDA) has approved Immunomedics’ antibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat triple-negative breast cancer (TNBC) patients who already tried at least two previous therapies for metastatic disease. ... Read more